Objective: This study investigated the clinical efficacy and value of fractional flow reserve (FFR) in guiding the treatment of borderline coronary lesions.
Introduction
Coronary artery angiography (CAG) is the gold standard for clinical diagnosis of coronary heart disease. Borderline coronary lesions are defined as lesion with stenosis ranging from 50% to 70% based on visual inspection of coronary angiography [1] . Borderline coronary lesions are common in patients with stable angina pectoris and acute coronary syndrome [2] . The FFR is recognized internationally as the best method by which to diagnose the degree of stenosis of coronary arteries, select the optimal treatment strategy, and assess efficacy [3] .
Subjects and methods
Forty-three patients with borderline coronary lesions (steno- Inclusion criteria (1) Patients who were aware of the content of the examination and surgery and signed an informed consent form. 
CAG and FFR measurement
The standard Judkins method was adopted for CAG and the standard method was adopted for FFR measurement. A 6F guiding catheter with no side opening was placed through a radial artery sheath to push a 0.014-inch pressure wire to the coronary artery orifice. A correction was made to ensure that the pressure tested by the guiding catheter and pressure by the pressure wire were consistent, then the 0.014-inch pressure wire (the pressure receptor was 3 cm away from the top of the guiding wire) was sent to the distal target vessel (the receptor was located 3-4 cm from the distal lesion). The top of the guiding wire was maintained in the middle of the vessel lumen without touching the vessel walls. ATP (drug concentration=1 mg/mL; infusion speed (mL/h)=weight (kg)×8.4) was pumped continuously by an 18G trocar through the median cubital vein. The pumping was stopped after 1-2 min when the coronary target vessel was induced to the maximum bloodshot state, and the instrument automatically displayed the FFR value. The receptor of the pressure wire was withdrawn from the catheter after each lesion test, and the difference between the aorta arterial pressure (Pa) and the average pressure of the guiding wire (Pd) was verified; thus, the presence of reality and reliability when the difference was within ±5 mmHg. For patients whose a FFR<0.75 and who needed further PCI, the FFR was re-measured after stent implantation. For patients with a FFR<0.90, dilation was performed after balloons were selected [4, 5] .
Grouping
The patients were divided into two groups according to the FFR value, with 0.75 as the boundary value. Twenty patients with a FFR≥0.75 were divided into the delayed PCI treatment group; a total of 21 patients had a FFR value <0.75 and were randomly divided into 2 groups, with one group referred to as the simple drug treatment group (11 patients and drug treatment group in short) and one group referred to as the PCI+drug treatment group (12 patients and the PCI group in short). All patients accepted optimal medical therapy after surgery.
Observational indices
All patients were followed for 6 months after surgery to observe adverse cardiovascular events (sudden cardiac death
[SCD], non-fatal MI, and revascularization) and recurrent angina. 
Statistical analysis

Results
Baseline characteristics of study patients
The differences in gender, age, hypertension, diabetes, hyperlipemia, family history, and ejection fraction among the three groups were not statistically significant (P>0.05), as shown in Table 1 . The differences in conventional drugs among the three groups were not statistically significant (P>0.05), as shown in Table 4 . Table 2 .
Comparisons of CAG parameters and FFR values
Comparisons of MACE and recurrent angina 6 months after treatment
No SCDs or MIs had occurred in any group of patients at the 6-month follow-up (P>0.05), but the incidence of revascularization differed among the 3 groups (P<0.05). The incidence of revascularization for patients in the drug treatment group among the groups with a FFR<0.75 was higher than the PCI and delayed PCI groups. The difference in recurrent angina among the three groups was statistically significant (P<0.05). Table 3 . In the PCI group among the groups with a FFR<0.75, 1 patient had recurrent angina and 1 patient had poor drug control; a recheck of the CAG indicated that the degree of stenosis of the original lesions was more severe than before. In the drug treatment group among the groups with a FFR<0.75, 3 patients had recurrent angina, among whom 2 had poor drug control; a recheck of the CAG indicated that the degree of stenosis of the original lesions was more severe than before and the lesions were relieved after stent implantation. In the delayed PCI group among the groups with a FFR≥0.75, 1 patient had recurrent angina and 1 patient had poor drug control, as shown in Table 4 .
Discussion
FFR is defined as ratio between the maximum blood flow of the myocardium in a stenotic coronary-dominated region and the theoretical maximum blood flow which the myocardium can achieve in the same coronary artery [6] . The FFR is calculated as the ratio between the distal pressure of coronary artery stenosis (Pd) tested by a pressure wire and the aortic pressure (Pa) simultaneously tested by a guiding catheter (FFR=Pd/ Pa). Therefore, the FFR value is not subject to the influence of blood pressure and heart rate, and has good repeatability and high accuracy, which makes the FFR feasible and reliable for clinical application [7] .
The FFR has become an internationally-recognized functional index for the assessment of coronary artery stenosis. The DEFER study [9] involved a 5-year follow-up after PCI given to patients with a single stenotic vessel, the purpose of which was to evaluate the appropriateness of performing PCI on stenotic lesions without functional significance. The study enrolled 335 patients with coronary borderline lesions, but without evidence of ischemia and divided the patients into 2 groups (a PCI group and a delayed PCI group). In the delayed PCI group, PCI treatment was delayed and only drug treatment was given for a FFR≥0.75, and the patients were designated as the "defer group." For a FFR<0.75, PCI was performed and the patients were designated as the "reference group." In the PCI group, for a FFR≥0.75, PCI was performed and the patients were designated as the "perform group."
For a FFR<0.75, the patients were designated as the "reference group." The prognosis among the defer, reference, and perform groups was compared. Clinical follow-up included the survival rate without cardiac events during the 5 years, and the results showed that the 5-year survival rate without cardiac events in the defer group was highest, followed by the perform and reference groups. The incidence of death and MI was 3.3% in the defer group, 7.9% in the perform group, and 15.7% in the reference group. For a FFR≥0.75, PCI treatment was much riskier and the survival rate was higher with respect to death and MIs. The study [9] showed that delayed PCI treatment for coronary borderline lesions in patients with a FFR≥0.75 is safe and feasible; specifically, the annual risk for cardiac death or MI was <1% and would not be decreased by stent implantation. Therefore, intervention on myocardial ischemia-free coronary artery stenosis is futile; FFR plays a guiding role in determining whether or not coronary artery stenosis results in distal myocardial ischemia.
In addition to the above studies, using a FFR<0.75 as the standard for borderline lesions inducing myocardial ischemia, a series of studies [10] [11] [12] [13] re-explored the guiding significance of this index in interventional therapy. One retrospective study [11] All patients had multiple vessel lesions (at least 2 branches of the 3 main coronary arteries had a diameter stenosis ≥50%)
based on CAG and were considered to need PCI surgery.
ORIGINAL RESEARCH
The patients were randomly divided into a CAG-guided PCI group and a FFR-guided PCI group. PCI was conducted for all lesions indicated by CAG in the CAG-guided PCI group, while in the FFR-guided group, the FFR was measured for all lesion-compromised coronary arteries and PCI was conducted on patients with a FFR≤0.8. The study endpoint was the 1-year incidence of MACE, including compound events of death, MIs, and revascularization. The secondary endpoint events included operative time, dose of contrast agent, and use of stents. The 1-year follow-up results showed that FFRguided PCI could improve the therapeutic effect on patients; the incidence of MACE decreased by 30% in the FFR-guided PCI group and the number of stents placed in each patient decreased from 2.7 to 1.9. The material cost for each surgery was reduced by 11%. The dose of contrast agent was also reduced significantly, but the operative time was not extended.
To understand the long-term clinical benefits, the FAME study released results from the 2-year follow-up and showed that the incidence of death and MI decreased by 34% in the FFRguided PCI group and the incidence of MI dropped by 37% when compared to the CAG-guided PCI group [18] . Among the 513 lesions with delayed intervention, only 1 induced a MI and only 10 clearly progressed, requiring revascularization. These findings affirmed the safety of performing delayed intervention for a FFR>0.8. The FAME study further showed a defect with respect to CAG; the measurement of FFR showed that among lesions with stenosis between 50% and 70% based on CAG, one-third of patients with ischemia were neglected.
Moreover, among the lesions with a stenosis >70% based on CAG, 20% patients without ischemia were excessively treated.
Among patients with 3-branch lesions based on CAG, measurement of FFR showed that only 14% had 3-branch lesions, 43% had 2-branch lesions, 34% had 1-branch lesions, and 9% of patients had no ischemia-induced changes.
The FAME II trial [19] was a prospective, multicenter, randomly-controlled clinical study that compared the clinical therapeutic effect on patients between FFR-guided PCI and optimal medical therapy (OMT), and observed the efficacy of using OMT to treat stable coronary heart disease. The participants of the study were patients with stable coronary artery disease who had 1-vessel, 2-vessel, or multiple-vessel lesions based on CAG and planned to undergo drug-eluting stent (DES) implantation. The FFR was measured in all patients, and patients with a FFR>0.8 were placed in the "register group" and treated with OMT. The patients with a FFR<0.8 were placed in the random "reference group" and distributed to the PCI+OMT and OMT groups with a 1:1 ratio. Clinical therapeutic effects were followed for 1 month, The FAME III trial [21] compared the long-term efficacy of FFR-guided PCI and CABG. The previous SYNTAX study [22] showed that CABG efficacy was better than PCI for high-risk patients whose SYNTAX was >33. However, after FFR functional SYNTAX scoring [23] , 32% of the patients were re-divided from the original high-risk group into lower risk groups. Specifically, 23% of the high-risk group was redivided into the medium-risk group and 15% into the low-risk group; 59% of the medium-risk group was re-divided into the low-risk group. By selecting the ischemic lesions with functional significance through FFR screening, then comparing the results of PCI and CABG, the groups were divided more precisely. The FAME III trial study compared the difference in long-term efficacy of FFR-guided PCI and CABG in patients with two-or three-vessel lesions (including the proximal segment of anterior descending branch or the left main artery), and it is believed that the results of this study will provide a more robust basis for the high-risk patients in the selection of PCI/ CABG strategies. 
